Volume 3.24 | Jun 19

Pancreatic Cell News 3.24 June 19, 2012
     In this issue: Publications | Science News | Industry News | Policy News | Events | Jobs 
Cell Therapy News on Facebook  Pancreatic Cell News on Twitter
Unexpected Discovery Reveals Potential Therapeutic Target
A study of pancreas cells showed that removal of the Bcl-2 protein activated a molecule in the cell membrane which pumps calcium out of the cells. As the team expected, a lower level of Bcl-2 increased the level of programmed cell death. But they also found that the lack of Bcl-2 markedly protected against another much more dangerous form of cell death – necrosis. [Press release from Cardiff University discussing online prepublication in Current Biology] Press Release | Abstract

Ready Sep Go: Request a Free Cell Isolation Wallchart
PUBLICATIONS (Ranked by impact factor of the journal)


Expression of Endoplasmic Reticulum Stress Markers in the Islets of Patients with Type 1 Diabetes
Islets from individuals with type 1 diabetes showed increased levels of C/EBP homologous protein and, at least for insulitis-positive and beta cell-containing islets, immunoglobulin heavy chain. X-box binding protein 1 expression was not, however, increased. [Diabetologia] Abstract

The Regulation of Rasd1 Expression by Glucocorticoids and Prolactin Controls Peripartum Maternal Insulin Secretion
Immunofluorescent staining demonstrated that Rasd1 is localized within pancreatic β-cells. Data indicate that the stimulation of Rasd1 expression by glucocorticoid at the end of pregnancy reverses the increased insulin secretion that occurs during pregnancy. Prolactin negatively regulates this pathway by inhibiting glucocorticoid receptor/signal transducer and activator of transcription 5b transcriptional activity on the Rasd1 gene. [Endocrinology] Abstract

Agelaia MP-I: A Peptide Isolated from the Venom of the Social Wasp, Agelaia pallipes pallipes, Enhances Insulin Secretion in Mice Pancreatic Islets
The insulin secretion of isolated pancreatic islets from adult Swiss mice was evaluated in the presence of synthetic Agelaia MP-I peptide, and some mechanisms of action of this peptide on endocrine pancreatic function were characterized. [Toxicon] Abstract

Acute Hypoxia Induces Apoptosis of Pancreatic β-Cell by Activation of the Unfolded Protein Response and Upregulation of C/EBP Homologous Protein
Researchers observed that pancreatic islets of type 2 db/db diabetic mice were more hypoxic than their counterpart in normoglycemic animals. This finding indicates that hypoxia-mediated apoptosis may occur in type 2 diabetes. [Cell Death Dis] Full Article


Immunohistochemical Characteristics and Malignant Progression of Hepatic Cystic Neoplasms in Comparison with Pancreatic Counterparts
The immunohistochemical features of intraductal papillary neoplasm of the bile duct and hepatic mucinous cystic neoplasm were characterized and compared with those of similar pancreatic lesions, intraductal papillary mucinous neoplasm of the pancreas, and pancreatic mucinous cystic neoplasm and with those of other biliary cystic lesions, peribiliary cysts. [Hum Pathol] Abstract

M2-Polarized Tumor-Associated Macrophage Infiltration of Regional Lymph Nodes Is Associated with Nodal Lymphangiogenesis and Occult Nodal Involvement in pN0 Pancreatic Cancer
Researchers investigated the relationship of M2-polarized tumor-associated macrophage infiltration of the regional lymph nodes, nodal lymphangiogenesis, and occult nodal involvement in pN0 pancreatic cancer. [Pancreas] Abstract

Solid-Pseudopapillary Tumor of the Pancreas: Clinical Features, Pathological Characteristics, and Origin
Investigators aimed to study clinically pathological features and origin of solid-pseudopapillary tumor of pancreas. [J Surg Oncol] Abstract

High Dose Glargine Alters the Expression Profiles of MicroRNAs in Pancreatic Cancer Cells
Researchers investigated the effect of high dose glargine on the expression profiles of microRNAs in human pancreatic cancer cells. [World J Gastroenterol] Abstract

Prognostic Significance of ATM and Cyclin B1 in Pancreatic Neuroendocrine Tumor
The authors evaluated the clinical and prognostic significance of ataxia telangiectasia mutated kinase (ATM) and cyclin B1 in patients with pancreatic neuroendocrine tumors. [Tumor Biol] Abstract

Friends love mTeSR1, too. You and a friend can both receive a FREE bottle of mTeSR1. (Terms and conditions apply). Learn More.

RLIP76 Contributes to Pancreatic Cancer Cell Resistance to Chemotherapy and Radiation
Researchers have not only identified a protein that allows pancreatic cancer cells to resist therapy but also developed a way to block it. [Press release from EurekAlert! discussing research presented at the American Association for Cancer Research (AACR)’s Pancreatic Cancer: Progress and Challenges Conference, Lake Tahoe] Press Release

JDRF and Novo Nordisk Establish R&D Collaboration in Type 1 Diabetes
To address the underlying autoimmune process that is central to type 1 diabetes, JDRF and Novo Nordisk are partnering to discover and develop novel immunotherapies to prevent, treat, and help cure the disease. [Novo Nordisk A/S] Press Release

NewLink Updates Enrollment Information for Its Pivotal Phase III HyperAcute(R) Pancreas Immunotherapy (Algenpantucel-L) Trial
NewLink Genetics Corporation announced that in the second quarter of 2012 it passed the midpoint in enrollment in its Phase III HyperAcute Pancreas immunotherapy product candidate (algenpantucel-L) trial as number of participating institutions reached to 74 sites around the US. [NewLink Genetics Corporation]
Press Release

Osiris Receives Second Approval for Life-Saving Stem Cell Drug; Prochymal Granted Marketing Consent by New Zealand
Osiris Therapeutics, Inc. announced it has received consent from New Zealand to market its first-in-class stem cell therapy Prochymal® (remestemcel-L), for the treatment of acute graft-vs-host disease in children. With this decision New Zealand joins Canada, which last month became the world’s first internationally recognized regulatory authority to grant approval to a stem cell drug. [Osiris Therapeutics, Inc.]
Press Release


National Institutes of Health (United States)

Food and Drug Administration (United States)
Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

National Health Service (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 15th Canadian Diabetes Association (CDA)/Canadian Society of Endocrinology and Metabolism (CSEM) Professional Conference
October 10-13, 2012
Vancouver, Canada

Visit our events page to see a complete list of events in the pancreatic cell community.

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Postdoctoral Fellow – Department of Bioengineering and Barbara Davis Center (University of Colorado at Denver)

Postdoctoral Research Position for Minority Candidate (New York Obesity Research Center)

Clinical Coordinator (New York Obesity Nutrition Research Center)

Research Fellow in Diabetes Research (Monash University)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Pancreatic Cell News: Archives | Events | Contact Us